

**Curriculum Vitae**

**Adarsh S. Reddy M.D., PH.D.**

**Research Affiliations**

**Offices**

**Preferred Research Partners, Inc.**  
11219 Financial Centre Parkway, Suite 320  
Little Rock, AR 72211  
(501) 553-9987  
(501) 553-9986 FAX

**Preferred Research Partners Arkansas Center for Sleep Medicine**  
11219 Financial Center Parkway, Suite 101  
Little Rock, AR 72211  
(501) 553-9987  
(501) 553-9986 FAX

Signature: \_\_\_\_\_



Date: \_\_\_\_\_

05/21/2026

# ADARSH S. REDDY M.D., PH.D.

E-mail: [areddy@preferredresearchpartners.com](mailto:areddy@preferredresearchpartners.com)

Phone: 501-553-9987

## CONTACT INFORMATION

Preferred Research Partners, Inc. (Office)  
11219 Financial Centre Parkway, Suite 320  
Little Rock, AR 72211  
Main phone: (501) 553-9987  
Main fax: (501) 553-9986

Reddy Psychiatry, PLLC (Office)  
Address: 400 W. Capitol, Ste 1750, Little Rock, AR 72201  
Phone: (501) 500-9919  
Fax: (501) 441-2304  
Website: [www.ReddyPsychiatry.com](http://www.ReddyPsychiatry.com)

## CURRENT POSITION

### Private practice Psychiatrist (Apr 2021–Present)

- Reddy Psychiatry, PLLC
  - Adult and geriatric outpatient psychiatry with focus on mood, anxiety, trauma-related, psychotic, ADHD, and substance use disorders.

### Sub-Investigator / Aug 2025–Present

- Preferred Research Partners, Inc. Little Rock, AR 72211

## JOB EXPERIENCE

- **Attending Psychiatrist**
  - **Clara Maass Medical Center, Belleville, NJ (2017–2021):** Adult inpatient (involuntary), Psychiatric Emergency services, coverage for inpatient consults, Adult inpatient (voluntary), Telepsychiatry.
  - **Centrec Care Inc. (2019–2020):** Outpatient, partial hospitalization program (Locum Tenens).
  - **St. Louis County Department of Public Health (2019–2020):** Correctional-infirmery and outpatient (Locum Tenens).
  - **Trinitas Regional Medical Center, Elizabeth, NJ (2015–2017):** Psychiatric Emergency Services, child partial hospitalization program, adolescent outpatient clinic.

# ADARSH S. REDDY M.D., PH.D.

- **St. Michael's Medical Center, Newark, NJ (2015–2017):** Inpatient, ER consults, Substance Abuse Intensive Outpatient Program.

## EDUCATION AND TRAINING

- **Residency in Psychiatry**  
Washington University/Barnes-Jewish Hospital (2011 – 2015)
- **Ph.D. in Neuroscience**  
Washington University in St. Louis, MO (2011)  
Thesis Mentor: Mark Sands  
Thesis title: The role of inflammation in the pathogenesis and treatment of globoid-cell leukodystrophy
- **Clinical Internship**  
St. John's Medical College Hospital, Bangalore, India (Jul 2002–Feb 2003; Aug 2003–Feb 2004)
- **Research trainee**  
National Center for Biological Sciences, Bangalore, India (Feb 15, 2003–Aug 15, 2003) Dr. Sumantra Chattarji's Lab  
Project title: "Effects of chronic stress on behavior and cellular morphology in the amygdala"
- **M.B., B.S. (Bachelor of Medicine and Bachelor of Surgery)- equivalent of MD**  
St. John's Medical College, Bangalore, India (2002)

## MEDICAL LICENSE AND CERTIFICATIONS

- **Medical Licenses:**  
Arkansas (E-13265): Issued May 2020, Expires Jul 2026
- **Controlled Substance Licenses:**  
DEA / Buprenorphine (FR5330357 / XR5330357): Issued Mar 2024, Expires Apr 2027
- **Certifications:**
  - ECFMG (0-669-114-1): Issued Aug 2009
  - ABPN (70425): Issued Dec 2025, Expires Dec 2027

# ADARSH S. REDDY M.D., PH.D.

## AWARDS

1. The Eli Robins Award for Excellence in Clinical Psychiatry, Teaching and Research, and in Recognition of Potential for Leadership in Academic Medicine, Washington University, Department of Psychiatry, 2015.
2. Best Student (academic) among the graduating class of 2004, St. John's Medical College, Bangalore, India
3. Special Prizes: Anatomy, Physiology, Biochemistry, Microbiology, Surgery, Dermatology
4. Certificate of Honor: Anatomy, physiology, biochemistry, pharmacology, Ophthalmology
5. Certificate of Merit: Pathology, Microbiology

## SCHOLAR PROFILE

[Link to Google Scholar profile](#)

## PUBLICATIONS

1. Hawkins-Salsbury JA, **Reddy AS**, Sands MS. Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts? *Hum Mol Genet.* 2011 Apr 15;20(R1):R54-60.
2. **Reddy AS**, Kim JH, Hawkins-Salsbury JA, Macauley SL, Tracy ET, Vogler CA, Han X, Song SK, Wozniak DF, Fowler SC, Klein RS, Sands MS. Bone marrow transplantation augments the effect of brain- and spinal cord-directed adeno-associated virus 2/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophy. *J Neurosci.* 2011 Jul 6;31(27):9945-57.
3. Hawkins-Salsbury JA, Qin EY, **Reddy AS**, Vogler CA, Sands MS. Oxidative stress as a therapeutic target in globoid cell leukodystrophy. *Exp Neurol.* 2012 Oct;237(2):444-52.
4. Qin EY, Hawkins-Salsbury JA, Jiang X, **Reddy AS**, Farber NB, Ory DS, Sands MS. Bone marrow transplantation increases efficacy of central nervous system-directed enzyme replacement therapy in the murine model of globoid cell leukodystrophy. *Mol Genet Metab.* 2012 Sep;107(1-2):186-96.
5. Macauley SL, Roberts MS, Wong AM, McSloy F, **Reddy AS**, Cooper JD, Sands MS. Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis. *Ann Neurol.* 2012 Jun;71(6):797-804.
6. **Reddy AS**, Wozniak DF, Farber NB, Dearborn JT, Fowler SC, Sands MS. Bone Marrow Transplantation Alters the Tremor Phenotype in the Murine Model of Globoid-Cell Leukodystrophy. *J Clin Med.* 2012 Jan 19;1(1):1-14. PubMed PMID: 24013457.
7. **Reddy AS**, Patel JR, Vogler C, Klein RS, Sands MS. Central nervous system pathology progresses independently of KC and CXCR2 in globoid-cell leukodystrophy. *PLoS One.* 2013 Jun 3;8(6):e64647.
8. Hawkins-Salsbury JA., Shea L, Jiang X, Hunter D, **Reddy AS**, Qin EY, Li Y, Gray SJ, Ory DS, Sands MS. Mechanism-Based Combination Treatment Dramatically Increases Therapeutic Efficacy in

# ADARSH S. REDDY M.D., PH.D.

Murine Globoid Cell Leukodystrophy. *J Neurosci.* 2015, 35(16): 6495-6505

9. **Reddy AS\***, O'Brien D\*, Pisat N, Weichselbaum CT, Sakers K, Lisci M, Dalal JS, Dougherty JD. A Comprehensive Analysis of Cell Type-Specific Nuclear RNA From Neurons and Glia of the Brain. *Biol Psychiatry.* 2016 Feb 24. Pii: S0006-3223(16)00133-5.
10. **Reddy AS.** Secondary prevention of antipsychotic-induced hyperprolactinemia. *American Journal of Psychiatry Residents' Journal.* 2015 Feb; 2 (10): 3-5.

## TALKS

1. Forebrain, cerebellar, and spinal cord-directed AAV2/5 gene therapy augments the therapeutic effect of bone marrow transplantation in a murine model of globoid cell leukodystrophy. (Nanosymposium: Demyelinating disorders-cellular mechanisms. The Society for Neuroscience annual meeting, San Diego, CA, November 14, 2010).
2. Bone marrow transplantation worsens the altered olivocerebellar dynamics in a murine model of globoid cell leukodystrophy (Nanosymposium: Demyelinating disorders-cellular mechanisms. The Society for Neuroscience annual meeting, San Diego, CA, November 14, 2010).
3. Combination Gene Therapy and Bone Marrow Transplantation for Krabbe's disease; "Towards Clinical Progress in the Mucopolysaccharidoses" meeting; Washington D.C. March 7-8, 2007.
4. Treatment approaches to syndromic autism: ideas from globoid-cell leukodystrophy; University of Pittsburgh Medical Center, Dec 17, 2014.
5. Cell-type specific coding and non-coding RNA in the CNS; Annual meeting of the American Society of Clinical Psychopharmacology, Scottsdale, Arizona, May 29, 2016.

## POSTER PRESENTATIONS

1. Reddy, A.S., et al., The role of the chemokine KC in the pathogenesis of globoid cell leukodystrophy. International Society for Neuroimmunology meeting; Fort Worth, Texas, 2008.
2. Reddy, A.S., et al., The role of chemokine receptor CXCR2 in the pathogenesis of globoid-cell leukodystrophy. Poster 2009-S-4395-SfN. SFN Annual Meeting, Chicago, 2009

## EDITORIAL EXPERIENCE

Guest Editor: *American Journal of Psychiatry Residents Journal* (theme: "Biological Psychiatry", July 2015).

## MEMBERSHIPS

- American Medical Association

# ADARSH S. REDDY M.D., PH.D.

- American Psychiatric Association

## CLINICAL RESEARCH EXPERIENCE

- **2021:** AbbVie – Pediatric Migraine (Study ID: 3110-305-002)
- **2021:** AbbVie – Pediatric Migraine (Study ID: 3110-306-002)
- **2023:** AbbVie – Pediatric Episodic Migraine (Study ID: M21-199)
- **2023:** AbbVie – Pediatric Episodic Migraine (Study ID: M21-201)
- **2023:** Supernus – Pediatric ADHD (Study ID: 812P401)
- **2023:** Usona – Major Depressive Disorder (Study ID: PSIL301)
- **2024:** Axsome – Excessive Daytime Sleepiness with Shift Work Disorder (Study ID: SOL-SWD-301)
- **2024:** AbbVie – Menstrual Migraine Prevention (Study ID: M23-714)
- **2024:** Phathom – Eosinophilic Esophagitis (Study ID: EoE-201)
- **2024:** Alto Neuroscience – Bipolar Depression (Study ID: ALTO-100-211)
- **2024:** MindMed – Generalized Anxiety Disorder (Study ID: MM120-301)
- **2025:** AbbVie – Pediatric Chronic Migraine ages 12-17 y/o (Study ID: M23-712)
- **2025:** Alkermes – Idiopathic Hypersomnia (Study ID: ALKS2680-203)
- **2025:** Alkermes – Narcolepsy (Study ID: ALKS2680-301)
- **2025:** MindMedicine, Inc. – Major Depressive Disorder (MDD) (Study ID: MM123-310 (EMERGE))
- **2025:** Atai Pharmaceuticals – Treatment Resistant Depression (TRD) (Study ID: VLS-01-203)
- **2025:** Mirador Therapeutics, Inc. – Active Crohn's Disease or Active Ulcerative Colitis (Study ID: MT-100-201/PROBEUC/PROBECD)
- **2025:** Eli Lilly & Company – Moderately to Severely Active Ulcerative Colitis (Study ID: I7J-MCDSAG)
- **2025:** Axsome Therapeutics – Fibromyalgia (Study ID: AXS-14-FM-301)
- **2025:** Sanofi-Aventis – Induction study Moderately to Severely Active Ulcerative Colitis (Study ID: EFC18325)
- **2025:** Sanofi-Aventis – Induction study Moderately to Severely Active Crohn's Disease (Study ID: EFC18326)
- **2026:** AbbVie – MDD (Study ID: M25-987)